Drug-Drug Interactions, Safety, and Pharmacokinetics of EGFR Tyrosine Kinase Inhibitors for the Treatment of Non–Small Cell Lung Cancer
Colleen R. Kucharczuk,(1) DNP, CRNP, Alex Ganetsky,(1) PharmD, BCOP, and J. Michael Vozniak,(2) PharmD, BCOP
1)Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania; 2)Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania at the time of article submission, currently at Merck & Co., Inc, Kenilworth, New Jersey
Authors’ disclosures of conflicts of interest are found at the end of this article.
Colleen Kucharczuk, DNP, CRNP, 3400 Spruce Street, Philadelphia, PA 19104. E-mail: firstname.lastname@example.org
J Adv Pract Oncol 2018;9(2):189–200 |
© 2018 Harborside™
Inhibitors of the epidermal growth factor receptor (EGFR) are important treatment options for non–small cell lung cancer (NSCLC) patients with activating EGFR mutations. Erlotinib, gefitinib, afatinib, and osimertinib are approved for use in NSCLC patients, and several other agents are in clinical development. The objectives of this article are to review the pharmacokinetic and known drug interaction data for EGFR tyrosine kinase inhibitors (TKIs) available for use in NSCLC patients, as well as adverse events (AEs) commonly observed with EGFR-TKI treatment, and to discuss relevant management strategies. The importance of this information for patient care is explored from the perspective of advanced practitioners. Pharmacokinetic, drug-interaction, and safety data are included for EGFR inhibitors approved for NSCLC (erlotinib, gefitinib, afatinib, and osimertinib). Relevant dose modifications and AE management strategies are also reviewed. The interdisciplinary health-care team plays an essential role in patient education, care planning, and medication administration. As such, it is essential that advanced practitioners understand the safety profiles and the potential for drug interactions with EGFR TKIs to ensure patients achieve the maximum benefit from these agents.
For access to the full length article, please sign in